Oral penicillins are associated with less frequent anaphylaxis reactions than parenterally-administered penicillins, but rates are low for both routes, according to new research.
Quality of life and other patient-reported outcomes significantly improved in patients receiving low- and mid-dose fluticasone propionate (Fp) and fluticasone propionate/salmeterol (FS) via a novel multidose dry powder inhaler (MDPI) versus placebo
Reslizumab appears to improve clinical asthma exacerbation rates among patients with Aspirin Exacerbated Respiratory Disease (AERD)
Study data from a randomized, double-blind, placebo-controlled trial of prasugrel for the treatment of AERD presented at the 2017 AAAAI Annual Meeting.
Want to read more?
Please login or register first to view this content.